Filter posts

Send us Your BIO 2016 Session and Speaker Ideas

Even though BIO 2015 in Philadelphia was just two months ago, we already are hard …

Jim Greenwood asks: How prepared are we for avian flu?

As a serious avian influenza outbreak continues to wreak havoc on poultry farms across the …

Welcome to Philadelphia and to BIO 2015!

Over the course of the next few days, you will have the opportunity to hear …

Jim Greenwood in New York Times: Specialty Tiers Limit Patient Access

Today, the New York Times published a letter from Jim Greenwood, BIO’s President and CEO. …

Jim Greenwood on the Road: Opening Bell at NASDAQ

Jim Greenwood, BIO’s President and CEO, rang the opening bell this morning at the NASDAQ …

The Value of Innovation to Save and Transform Lives

Patients have greater hope for cures to today’s most complex and challenging diseases thanks to …

When The Deck is Stacked Against Innovators, Everyone Loses

Yesterday, I took part in a series of successful meetings on Capitol Hill regarding the …

Updated Legal and Regulatory Frameworks Needed for Biosimilars

Biosimilars raise novel and complex questions of science and law that require updated legal and …

Attacks on Venture Philanthropy Miss Mark Badly

In a highly problematic op-ed in today’s New York Times, freelance journalist Llewellyn Hinkes-Jones attacked venture philanthropy …

Wall Street Journal Highlights Promising Gene Therapy Advances

Yesterday, bluebird bio reported some very uplifting news at the annual meeting of the American …